Advanced Search
Contact | Corporate | Help

Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With CLL

Sponsors:
  • Sarah Cannon Research Institute
  • Celgene Corporation
  • Genentech
Phases:
  • Phase I
  • Phase II
IndicationsAcronym:
  • Chronic Lymphocytic Leukemia
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: lenalidomide, fludarabine and rituximab
Enrollment:
40

Additional information about NCT00536341.


SourceSolution © 2008-2012